We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.21%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$290M
AUM Growth
+$16.2M
Cap. Flow
-$4.34M
Cap. Flow %
-1.5%
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.3M
2
GEV icon
GE Vernova
GEV
+$2.82M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.76M
4
DYN icon
Dyne Therapeutics
DYN
+$2.61M
5
AMZN icon
Amazon
AMZN
+$2.59M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.02M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$3.97M
4
MRUS
Merus
MRUS
+$2.23M
5
META icon
Meta Platforms (Facebook)
META
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 46.45%
2 Technology 15.69%
3 Consumer Discretionary 9.1%
4 Industrials 4.98%
5 Financials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
126
Cytokinetics
CYTK
$10.6B
$531K 0.18%
+10,055
New +$560K
MIRM icon
127
Mirum Pharmaceuticals
MIRM
$5.99B
$529K 0.18%
13,571
-6,637
-33% -$265K
ANAB icon
128
AnaptysBio
ANAB
$1.71B
$522K 0.18%
+15,574
New +$532K
IMTX icon
129
Immatics
IMTX
$1.33B
$520K 0.18%
45,544
-32,277
-41% -$382K
ETNB
130
DELISTED
89bio
ETNB
$494K 0.17%
+66,787
New +$562K
URGN icon
131
UroGen Pharma
URGN
$2.3B
$490K 0.17%
+38,566
New +$572K
IRON icon
132
Disc Medicine
IRON
$3.12B
$470K 0.16%
+9,565
New +$449K
MDGL icon
133
Madrigal Pharmaceuticals
MDGL
$12.4B
$469K 0.16%
2,211
-323
-13% -$82.6K
TSVT
134
DELISTED
2seventy bio
TSVT
$451K 0.16%
95,454
+1,954
+2% +$8.81K
NTRA icon
135
Natera
NTRA
$45.1B
$437K 0.15%
3,440
-128
-4% -$14.7K
ALNY icon
136
Alnylam Pharmaceuticals
ALNY
$29.6B
$427K 0.15%
1,551
-1,051
-40% -$274K
PHVS icon
137
Pharvaris
PHVS
$2.41B
$422K 0.15%
22,768
+6,018
+36% +$110K
KURA icon
138
Kura Oncology
KURA
$882M
$413K 0.14%
21,161
+4,397
+26% +$89.1K
ACAD icon
139
Acadia Pharmaceuticals
ACAD
$5.07B
$389K 0.13%
25,287
-591
-2% -$9.86K
KALV
140
DELISTED
KalVista Pharmaceuticals
KALV
$386K 0.13%
33,305
+1,432
+4% +$18K
TYRA icon
141
Tyra Biosciences
TYRA
$1.5B
$378K 0.13%
16,078
– –
CLDX icon
142
Celldex Therapeutics
CLDX
$3.48B
$305K 0.11%
8,981
-646
-7% -$24.6K
AMD icon
143
Advanced Micro Devices
AMD
$774B
– –
-6,900
Closed -$1.12M
ASND icon
144
Ascendis Pharma A/S
ASND
$16.7B
– –
-4,527
Closed -$617K
BFAM icon
145
Bright Horizons
BFAM
$3.76B
– –
-11,800
Closed -$1.3M
BILI icon
146
Bilibili
BILI
$7.53B
– –
-46,857
Closed -$723K
CABA icon
147
Cabaletta Bio
CABA
$455M
– –
-22,208
Closed -$166K
CRWD icon
148
CrowdStrike
CRWD
$226B
– –
-12,800
Closed -$1.23M
DUOL icon
149
Duolingo
DUOL
$6.34B
– –
-7,400
Closed -$1.54M
EDU icon
150
New Oriental
EDU
$8.84B
– –
-4,600
Closed -$358K
3 4 5
6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2024 Portfolio in Review

As of Q3 2024, HighVista Strategies held 174 positions worth $290M, up 5.9% from $274M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies's Q3 2024 filing shows 37 new, 46 increased, 48 reduced and 32 closed positions. Its largest new stake was Amgen: 10,101 shares worth $3.25M. The largest sale was Insmed, an estimated $6M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q3 2024 buy was Amgen: 10,101 shares worth $3.25M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q3 2024, an estimated $2.76M increase.
  • HighVista Strategies's biggest Q3 2024 reduction was Insmed, cutting an estimated $6M.
  • HighVista Strategies fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $4.02M.
  • HighVista Strategies's ten largest holdings make up 26% of its $290M portfolio in Q3 2024.
  • HighVista Strategies opened 37 new positions and closed 32 in Q3 2024.
  • HighVista Strategies's portfolio value rose 5.9% quarter-over-quarter to $290M.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.